{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:14:21Z","timestamp":1783617261299,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>MRI has transformed prostate cancer diagnosis, risk stratification, and treatment planning. However, the tumour-node-metastasis (TNM) classification continues to rely exclusively on digital rectal examination (DRE) for clinical T-staging, despite DRE\u2019s limited diagnostic accuracy and prognostic performance. This mismatch between modern MRI practice and outdated staging criteria undermines prognostication and treatment decision-making. In this review, we synthesise current evidence on DRE- and MRI-based local staging, discuss the limitations of the current TNM framework, and present a proposal for parallel reporting of MRI-based T-staging (mrT) alongside clinical T-staging (cT). We further outline the rationale for developing MRI-derived prognostic groups, benchmarked against pathology and long-term oncologic outcomes, and present a framework intended to support future evidence-based revisions of the official TNM classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>Clinical adoption of prostate MRI, TNM T-staging still relies on digital rectal examination, a method with limited sensitivity and prognostic value. This discordance leads to stage misclassification and suboptimal risk stratification. Parallel reporting of MRI-based T-staging and development of MRI-derived prognostic groups are essential to align staging with contemporary imaging practice, support evidence-based treatment decisions, and inform future revisions of the TNM classification system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Digital rectal examination (DRE) is inferior to MRI for detecting extraprostatic extension.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>MRI-based and DRE-based T-staging should be reported separately to evaluate stage migration, as MRI-based T-staging may shift patients into higher stages without reflecting true biological risk.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Parallel reporting of MRI-based T-staging and development of MRI-derived prognostic groups are essential to align staging with contemporary imaging practice, support evidence-based treatment decisions, and inform future revisions of the TNM classification system.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-026-02346-w","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:32:14Z","timestamp":1783614734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating MRI-based tumour staging within the TNM classification system in modern prostate cancer management"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3752-1315","authenticated-orcid":false,"given":"Georgios","family":"Agrotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Purysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9042-7328","authenticated-orcid":false,"given":"Fredrik","family":"J\u00e4derling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Villeirs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-844X","authenticated-orcid":false,"given":"Samuel J.","family":"Withey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"de Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9804-0603","authenticated-orcid":false,"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2346_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, Van Den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"2346_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01588-9","volume":"18","author":"MG Parry","year":"2020","unstructured":"Parry MG, Cowling TE, Sujenthiran A et al (2020) Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation. BMC Med 18:114. https:\/\/doi.org\/10.1186\/s12916-020-01588-9","journal-title":"BMC Med"},{"key":"2346_CR3","unstructured":"Brierley J, Giuliani M, O\u2019Sullivan B et al (2025) TNM classification of malignant tumours, 9th edn. Wiley, Hoboken"},{"key":"2346_CR4","unstructured":"Amin MB, American Joint Committee on Cancer, American Cancer Society (2017) AJCC cancer staging manual, 8th edn. American Joint Committee on Cancer, Springer, Chicago"},{"key":"2346_CR5","unstructured":"Roberts MJ, Teloken P, Chambers SK et al (2018) Table 8, TNM staging classifications (per American Joint Committee on Cancer (AJCC) 8th edition 2016)(198). Available via https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279042\/table\/prostate-cancer-det.primarytum\/. Accessed 23 Sept 2025"},{"key":"2346_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.urology.2020.08.089","volume":"147","author":"TFW Soeterik","year":"2021","unstructured":"Soeterik TFW, Van Melick HHE, Dijksman LM et al (2021) Multiparametric magnetic resonance imaging should be preferred over digital rectal examination for prostate cancer local staging and disease risk classification. Urology 147:205\u2013212. https:\/\/doi.org\/10.1016\/j.urology.2020.08.089","journal-title":"Urology"},{"key":"2346_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","volume":"7","author":"A Matsukawa","year":"2024","unstructured":"Matsukawa A, Yanagisawa T, Bekku K et al (2024) Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 7:697\u2013704. https:\/\/doi.org\/10.1016\/j.euo.2023.12.005","journal-title":"Eur Urol Oncol"},{"key":"2346_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/s0090-4295(95)96812-1","volume":"45","author":"DS Smith","year":"1995","unstructured":"Smith DS, Catalona WJ (1995) Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 45:70\u201374. https:\/\/doi.org\/10.1016\/s0090-4295(95)96812-1","journal-title":"Urology"},{"key":"2346_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/pros.20759","volume":"68","author":"C Gosselaar","year":"2008","unstructured":"Gosselaar C, Kranse R, Roobol MJ et al (2008) The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 68:985\u2013993. https:\/\/doi.org\/10.1002\/pros.20759","journal-title":"Prostate"},{"key":"2346_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","volume":"6","author":"A Krilaviciute","year":"2023","unstructured":"Krilaviciute A, Becker N, Lakes J et al (2023) Digital rectal examination is not a useful screening test for prostate cancer. Eur Urol Oncol 6:566\u2013573. https:\/\/doi.org\/10.1016\/j.euo.2023.09.008","journal-title":"Eur Urol Oncol"},{"key":"2346_CR11","doi-asserted-by":"publisher","unstructured":"Albers P, Miandashti N, Broomfield S, Kinnaird A (2025) Does the digital rectal exam still provide value in the age of MRI? Can Urol Assoc J. https:\/\/doi.org\/10.5489\/cuaj.9164","DOI":"10.5489\/cuaj.9164"},{"key":"2346_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.urology.2019.04.023","volume":"130","author":"C Draulans","year":"2019","unstructured":"Draulans C, Everaerts W, Isebaert S et al (2019) Impact of magnetic resonance imaging on prostate cancer staging and European Association of Urology risk classification. Urology 130:113\u2013119. https:\/\/doi.org\/10.1016\/j.urology.2019.04.023","journal-title":"Urology"},{"key":"2346_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N et al (2024) NCCN Guidelines\u00ae insights: prostate cancer, version 3.2024: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 22:140\u2013150. https:\/\/doi.org\/10.6004\/jnccn.2024.0019","journal-title":"J Natl Compr Canc Netw"},{"key":"2346_CR14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jamaoncol.2024.3196","volume":"10","author":"N Mookerji","year":"2024","unstructured":"Mookerji N, Pfanner T, Hui A et al (2024) Fluorine-18 Prostate-Specific Membrane Antigen\u20131007 PET\/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer. JAMA Oncol 10:1097\u20131103. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3196","journal-title":"JAMA Oncol"},{"key":"2346_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2214\/AJR.15.15878","volume":"207","author":"RT Gupta","year":"2016","unstructured":"Gupta RT, Brown AF, Silverman RK et al (2016) Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer. AJR Am J Roentgenol 207:87\u201395. https:\/\/doi.org\/10.2214\/AJR.15.15878","journal-title":"AJR Am J Roentgenol"},{"key":"2346_CR16","doi-asserted-by":"publisher","first-page":"106.e9","DOI":"10.1016\/j.urolonc.2022.10.023","volume":"41","author":"A Rakauskas","year":"2023","unstructured":"Rakauskas A, Peters M, Ball D et al (2023) The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: a Will Rogers phenomenon. Urol Oncol Semin Orig Invest 41:106.e9\u2013106.e16. https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.023","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"2346_CR17","doi-asserted-by":"publisher","unstructured":"Agrotis G, Ursprung S, Van Der Steen C et al (2026) Pretreatment MRI as a prognostic factor after radical prostatectomy: a systematic review and meta-analysis. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2026.0371","DOI":"10.1001\/jamaoncol.2026.0371"},{"key":"2346_CR18","doi-asserted-by":"publisher","unstructured":"Withey SJ, Caglic I, Barrett T (2025) Prostate MRI in the UK: a survey of current practice by the British Society of Urogenital Radiology. Br J Radiol. https:\/\/doi.org\/10.1093\/bjr\/tqaf312","DOI":"10.1093\/bjr\/tqaf312"},{"key":"2346_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41391-024-00896-y","volume":"28","author":"SJC Soerensen","year":"2025","unstructured":"Soerensen SJC, Li S, Langston ME et al (2025) Trends in pre-biopsy MRI usage for prostate cancer detection, 2007\u20132022. Prostate Cancer Prostatic Dis 28:519\u2013522. https:\/\/doi.org\/10.1038\/s41391-024-00896-y","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2346_CR20","doi-asserted-by":"publisher","first-page":"e00019","DOI":"10.1097\/JU9.0000000000000246","volume":"3","author":"M Goldman","year":"2025","unstructured":"Goldman M, Arenas-Gallo C, Balasubramanian A et al (2025) Utilization of prebiopsy magnetic resonance imaging for prostate cancer detection. JU Open Plus 3:e00019. https:\/\/doi.org\/10.1097\/JU9.0000000000000246","journal-title":"JU Open Plus"},{"key":"2346_CR21","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J et al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403:1683\u20131722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2","journal-title":"Lancet"},{"key":"2346_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2214\/AJR.20.24268","volume":"216","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, Barentsz JO, Bittencourt LK et al (2021) PI-RADS Committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review. AJR Am J Roentgenol 216:3\u201319. https:\/\/doi.org\/10.2214\/AJR.20.24268","journal-title":"AJR Am J Roentgenol"},{"key":"2346_CR23","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2025.13722","volume":"334","author":"ABCD Ng","year":"2025","unstructured":"Ng ABCD, Asif A, Agarwal R et al (2025) Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial. JAMA 334:1170. https:\/\/doi.org\/10.1001\/jama.2025.13722","journal-title":"JAMA"},{"key":"2346_CR24","doi-asserted-by":"publisher","first-page":"109804","DOI":"10.1016\/j.ejrad.2021.109804","volume":"141","author":"I Caglic","year":"2021","unstructured":"Caglic I, Sushentsev N, Shah N et al (2021) Comparison of biparametric versus multiparametric prostate MRI for the detection of extracapsular extension and seminal vesicle invasion in biopsy na\u00efve patients. Eur J Radiol 141:109804. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109804","journal-title":"Eur J Radiol"},{"key":"2346_CR25","doi-asserted-by":"publisher","unstructured":"Agrotis G, Ursprung S, Schoots IG (2025) Personalised prostate MRI: tailoring contrast medium use in an era of increasing demand. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-11755-2","DOI":"10.1007\/s00330-025-11755-2"},{"key":"2346_CR26","doi-asserted-by":"publisher","first-page":"e2432588","DOI":"10.2214\/AJR.24.32588","volume":"225","author":"IG Schoots","year":"2025","unstructured":"Schoots IG, Haider MA, Punwani S, Padhani AR (2025) MRI in prostate cancer screening: a review and recommendations, from the AJR Special Series on Screening. AJR Am J Roentgenol 225:e2432588. https:\/\/doi.org\/10.2214\/AJR.24.32588","journal-title":"AJR Am J Roentgenol"},{"key":"2346_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/jpm15070284","volume":"15","author":"S Ursprung","year":"2025","unstructured":"Ursprung S, Agrotis G, Van Houdt PJ et al (2025) Prostate MRI using deep learning reconstruction in response to cancer screening demands\u2014a systematic review and meta-analysis. J Pers Med 15:284. https:\/\/doi.org\/10.3390\/jpm15070284","journal-title":"J Pers Med"},{"key":"2346_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M De Rooij","year":"2016","unstructured":"De Rooij M, Hamoen EHJ, Witjes JA et al (2016) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 70:233\u2013245. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.029","journal-title":"Eur Urol"},{"key":"2346_CR29","doi-asserted-by":"publisher","first-page":"112363","DOI":"10.1016\/j.ejrad.2025.112363","volume":"191","author":"G Agrotis","year":"2025","unstructured":"Agrotis G, Woo S, J\u00e4derling F et al (2025) Radiological T-staging in prostate cancer: towards a universal MRI-based scoring system. Eur J Radiol 191:112363. https:\/\/doi.org\/10.1016\/j.ejrad.2025.112363","journal-title":"Eur J Radiol"},{"key":"2346_CR30","doi-asserted-by":"publisher","first-page":"W73","DOI":"10.2214\/AJR.14.13600","volume":"205","author":"A Wibmer","year":"2015","unstructured":"Wibmer A, Vargas HA, Donahue TF et al (2015) Diagnosis of extracapsular extension of prostate cancer on prostate MRI: impact of second-opinion readings by subspecialized genitourinary oncologic radiologists. AJR Am J Roentgenol 205:W73\u2013W78. https:\/\/doi.org\/10.2214\/AJR.14.13600","journal-title":"AJR Am J Roentgenol"},{"key":"2346_CR31","doi-asserted-by":"publisher","first-page":"355.e1","DOI":"10.1016\/j.urolonc.2023.05.004","volume":"41","author":"T Chandrasekar","year":"2023","unstructured":"Chandrasekar T, Denisenko A, Mico V et al (2023) Multiparametric MRI is not sufficient for prostate cancer staging: a single institutional experience validated by a multi-institutional regional collaborative. Urol Oncol Semin Orig Invest 41:355.e1\u2013355.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2023.05.004","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"2346_CR32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/08465371211073158","volume":"73","author":"I Caglic","year":"2022","unstructured":"Caglic I, Sushentsev N, Shah N et al (2022) Integration of prostate biopsy results with pre-biopsy multiparametric magnetic resonance imaging findings improves local staging of prostate cancer. Can Assoc Radiol J 73:515\u2013523. https:\/\/doi.org\/10.1177\/08465371211073158","journal-title":"Can Assoc Radiol J"},{"key":"2346_CR33","doi-asserted-by":"publisher","unstructured":"Somford DM, Hamoen EH, F\u00fctterer JJ et al (2013) The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. https:\/\/doi.org\/10.1016\/j.juro.2013.05.021","DOI":"10.1016\/j.juro.2013.05.021"},{"key":"2346_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.15386\/mpr-1390","volume":"93","author":"C Popi\u021ba","year":"2020","unstructured":"Popi\u021ba C, Popi\u0163a A-R, Andrei A et al (2020) Local staging of prostate cancer with multiparametric-MRI: accuracy and inter-reader agreement. Med Pharm Rep 93:150\u2013161. https:\/\/doi.org\/10.15386\/mpr-1390","journal-title":"Med Pharm Rep"},{"key":"2346_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/PAP.0b013e31820cb506","volume":"18","author":"SM Falzarano","year":"2011","unstructured":"Falzarano SM, Magi-Galluzzi C (2011) Prostate cancer staging and grading at radical prostatectomy over time. Adv Anat Pathol 18:159\u2013164. https:\/\/doi.org\/10.1097\/PAP.0b013e31820cb506","journal-title":"Adv Anat Pathol"},{"key":"2346_CR36","doi-asserted-by":"publisher","unstructured":"Bertini A, Stephens A, Finocchiaro A et al (2025) Long-term cancer control outcomes after robot-assisted radical prostatectomy in pathologically non\u2013organ-confined high-risk prostate cancer: 20-year report from a single tertiary referral center. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2025.07.007","DOI":"10.1016\/j.euf.2025.07.007"},{"key":"2346_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.euo.2023.08.005","volume":"7","author":"UG Falagario","year":"2024","unstructured":"Falagario UG, Knipper S, Pellegrino F et al (2024) Prostate cancer\u2013specific and all-cause mortality after robot-assisted radical prostatectomy: 20 years\u2019 report from the European Association of Urology Robotic Urology Section Scientific Working Group. Eur Urol Oncol 7:705\u2013712. https:\/\/doi.org\/10.1016\/j.euo.2023.08.005","journal-title":"Eur Urol Oncol"},{"key":"2346_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.urology.2014.08.025","volume":"85","author":"MW Ball","year":"2015","unstructured":"Ball MW, Partin AW, Epstein JI (2015) Extent of extraprostatic extension independently influences biochemical recurrence-free survival: evidence for further pT3 subclassification. Urology 85:161\u2013164. https:\/\/doi.org\/10.1016\/j.urology.2014.08.025","journal-title":"Urology"},{"key":"2346_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2014.06.015","volume":"67","author":"BC Jeong","year":"2015","unstructured":"Jeong BC, Chalfin HJ, Lee SB et al (2015) The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. Eur Urol 67:342\u2013346. https:\/\/doi.org\/10.1016\/j.eururo.2014.06.015","journal-title":"Eur Urol"},{"key":"2346_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93340-3","volume":"11","author":"CK Park","year":"2021","unstructured":"Park CK, Chung YS, Choi YD et al (2021) Revisiting extraprostatic extension based on invasion depth and number for new algorithm for substaging of pT3a prostate cancer. Sci Rep 11:13952. https:\/\/doi.org\/10.1038\/s41598-021-93340-3","journal-title":"Sci Rep"},{"key":"2346_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.eururo.2015.07.045","volume":"70","author":"AR Padhani","year":"2016","unstructured":"Padhani AR, Petralia G, Sanguedolce F (2016) Finding minimal extraprostatic disease: who cares. Eur Urol 70:246\u2013247. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.045","journal-title":"Eur Urol"},{"key":"2346_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/his.12199","volume":"63","author":"D Danneman","year":"2013","unstructured":"Danneman D, Wiklund F, Wiklund NP, Egevad L (2013) Prognostic significance of histopathological features of extraprostatic extension of prostate cancer. Histopathology 63:580\u2013589. https:\/\/doi.org\/10.1111\/his.12199","journal-title":"Histopathology"},{"key":"2346_CR43","doi-asserted-by":"publisher","unstructured":"Daouacher G, Carlsson J, Voulgarakis N et al (2025) Diagnostic performance of conventional MRI using T1W and T2W for primary lymph node staging in intermediate- and high-risk prostate cancer patients prior to pelvic lymph node dissection. Abdom Radiol (NY) https:\/\/doi.org\/10.1007\/s00261-025-05073-w","DOI":"10.1007\/s00261-025-05073-w"},{"key":"2346_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2478\/raon-2019-0021","volume":"53","author":"I Caglic","year":"2019","unstructured":"Caglic I, Kovac V, Barrett T (2019) Multiparametric MRI\u2014local staging of prostate cancer and beyond. Radiol Oncol 53:159\u2013170. https:\/\/doi.org\/10.2478\/raon-2019-0021","journal-title":"Radiol Oncol"},{"key":"2346_CR45","doi-asserted-by":"publisher","first-page":"W95","DOI":"10.2214\/AJR.17.18481","volume":"210","author":"S Woo","year":"2018","unstructured":"Woo S, Suh CH, Kim SY et al (2018) The diagnostic performance of mri for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis. AJR Am J Roentgenol 210:W95\u2013W109. https:\/\/doi.org\/10.2214\/AJR.17.18481","journal-title":"AJR Am J Roentgenol"},{"key":"2346_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-013-0389-7","volume":"15","author":"AS Fortuin","year":"2014","unstructured":"Fortuin AS, Smeenk RJ, Meijer HJ et al (2014) Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential. Curr Urol Rep 15:389. https:\/\/doi.org\/10.1007\/s11934-013-0389-7","journal-title":"Curr Urol Rep"},{"key":"2346_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02100-0","volume":"21","author":"Y Yan","year":"2023","unstructured":"Yan Y, Liu Y, Li T et al (2023) Functional roles of magnetic nanoparticles for the identification of metastatic lymph nodes in cancer patients. J Nanobiotechnol 21:337. https:\/\/doi.org\/10.1186\/s12951-023-02100-0","journal-title":"J Nanobiotechnol"},{"key":"2346_CR48","doi-asserted-by":"publisher","first-page":"7266","DOI":"10.26355\/eurrev_202007_21879","volume":"24","author":"G Sun","year":"2020","unstructured":"Sun G, Zhang Y-X, Liu F, Tu N (2020) Whole-body magnetic resonance imaging is superior to skeletal scintigraphy for the detection of bone metastatic tumors: a meta-analysis. Eur Rev Med Pharmacol Sci 24:7266\u20137278. https:\/\/doi.org\/10.26355\/eurrev_202007_21879","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2346_CR49","doi-asserted-by":"publisher","unstructured":"Woo S, Russo L, Withey SJ et al (2025) ESUR: opportunities for PSMA-PET\/CT and whole-body MRI in advanced prostate cancer. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-12089-9","DOI":"10.1007\/s00330-025-12089-9"},{"key":"2346_CR50","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","volume":"62","author":"FE Lecouvet","year":"2012","unstructured":"Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99 m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68\u201375. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.020","journal-title":"Eur Urol"},{"key":"2346_CR51","doi-asserted-by":"publisher","first-page":"117955492513351","DOI":"10.1177\/11795549251335166","volume":"19","author":"MA Hassan","year":"2025","unstructured":"Hassan MA, Anpalakhan S, Campione M et al (2025) Magnetic resonance or computed tomography and bone scan for staging metastatic hormone\u2013sensitive prostate cancer. Clin Med Insights Oncol 19:11795549251335166. https:\/\/doi.org\/10.1177\/11795549251335166","journal-title":"Clin Med Insights Oncol"},{"key":"2346_CR52","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41391-018-0116-z","volume":"22","author":"F J\u00e4derling","year":"2019","unstructured":"J\u00e4derling F, Akre O, Aly M et al (2019) Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgery. Prostate Cancer Prostatic Dis 22:391\u2013398. https:\/\/doi.org\/10.1038\/s41391-018-0116-z","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2346_CR53","doi-asserted-by":"publisher","unstructured":"Agrotis G, J\u00e4derling F, Lakhani A et al (2026) ESR Essentials: MRI-based T-staging in prostate cancer\u2014practice recommendations by the European Society of Urogenital Radiology. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-026-12397-8","DOI":"10.1007\/s00330-026-12397-8"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-026-02346-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:32:15Z","timestamp":1783614735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-026-02346-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2346"],"URL":"https:\/\/doi.org\/10.1186\/s13244-026-02346-w","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.V. is a member of the Advisory Editorial Board of\n                      Insights into Imaging\n                      and, as such, did not participate in the selection or review processes for this article. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}